Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease.

Atherosclerosis is an inflammatory condition characterised by an abundance of activated immunocompetent cells in plaques which cause cardiovascular disease (CVD) when they rupture. Oxidized forms of low density lipoprotein (OxLDL) are a major constituent of atherosclerotic plaques and have proinflammatory effects, making oxLDL a candidate factor promoting atherosclerosis. In previous studies we and others demonstrated that platelet-activating factor (PAF)-like lipids in oxLDL may cause oxLDL-induced immune-stimulatory effects. A common denominator is phosphorylcholine (PC), a hapten-like epitope which is exposed on OxLDL and some microorganisms. We recently demonstrated that anti-PC has anti-inflammatory properties and that low levels of anti-PC predict the development of stroke and myocardial infarction. We hypothesize that low anti-PC represents a novel paradigm as a cause of chronic inflammatory diseases such as atherosclerosis where oxidized and/or inflammatory phospholipids play a role. It is possible that anti-PC can be used as a novel diagnostic tool and therapy in atherosclerotic disease. Copyright 2009 Elsevier Inc. All rights reserved.